Related Experiment Video
Updated: Feb 1, 2026
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Implementing a comprehensive translational oncology platform: from molecular testing to actionability
Zahi I Mitri1, Swapnil Parmar1, Brett Johnson1
1Oregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.
Background:
In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and analysis trial was implemented. This report describes our findings to date, including the frequency with which mutational testing led to precision-guided therapy and outcome for those patients.
Methods:
Eligible patients presenting to Oregon Health and Science University Knight Cancer Institute were enrolled on the study. Patients with biopsy proven metastatic or locally advanced unresectable prostate cancer, breast cancer, pancreatic adenocarcinoma, or refractory acute myelogenous leukemia receiving standard of care therapy were eligible. Metastatic site biopsies were collected and analyzed using the Knight Diagnostic Lab GeneTrails comprehensive solid tumor panel (124 genes). CLIA certified genomic information was made available to the treating physician.
Results:
Between 1/26/2017 and 5/30/2018, 38 patients were enrolled, with 28 successfully undergoing biopsy. Of these, 25 samples yielded sufficient tumor for analysis. The median biopsy cellularity and number of cores collected were 70% (15-90%) and 5 (2-20), respectively. No procedure-related complications occurred. GeneTrails analysis revealed that 22 of 25 (88%) tumor samples harbored at least one potentially actionable mutation, and 18 (72%) samples harbored 2 or more potentially actionable mutations. The most common genetic alterations identified involved: DNA damage repair genes, cell cycle regulating genes, PIK3CA/Akt/mTOR pathway, and FGF gene family. To date, CLIA certified genomic results were used by treating physicians for precision-guided therapy in 5 (23%) patients.
Conclusion:
We report the feasibility of real-time tissue acquisition and analysis to support a successful translational oncology platform. The workflow will provide the foundation to improve access and accrual to biomarker driven precision oncology trials.
Insights
A trial established real-time multi-omic analysis of patient tumors, revealing actionable mutations in 88% of samples. This workflow supports precision oncology by enabling biomarker-driven therapeutic interventions.
Area of Science:
- Translational Oncology
- Genomic Medicine
- Biomarker Discovery
Background:
- Implementing real-time multi-omic analysis for precision-guided therapy requires robust workflows.
- A tissue acquisition and analysis trial was conducted to establish these processes.
- The study aimed to determine the frequency of precision-guided therapy based on mutational testing and patient outcomes.
Observation:
- 38 patients with advanced cancers were enrolled; 28 underwent biopsy, yielding 25 analyzable tumor samples.
- No procedure-related complications were observed.
- High tumor cellularity (median 70%) and sufficient cores (median 5) were obtained.
Findings:
- 88% (22/25) of tumor samples had at least one actionable mutation; 72% (18/25) had two or more.
- Common alterations included DNA damage repair, cell cycle, PIK3CA/Akt/mTOR, and FGF pathway genes.
- CLIA-certified genomic results informed precision-guided therapy in 23% (5/25) of patients.
Implications:
- The study demonstrates the feasibility of real-time tissue acquisition and multi-omic analysis for a translational oncology platform.
- This workflow is foundational for improving access and enrollment in biomarker-driven precision oncology trials.
- Establishing efficient genomic analysis pipelines is crucial for advancing personalized cancer treatment.
Related Concept Videos
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:31Translation
Translation Produces the Building Blocks of Life
Proteins are...
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
01:44Termination of Translation
01:15Nursing Implementation
The five steps to implementing effective nursing care include reassessing the patient, reviewing and revising the existing nursing care plan, organizing the resources and care delivery, anticipating and preventing complications, and implementing nursing interventions.
02:07Improving Translational Accuracy